RU2729383C2 - Сконструированные высокоаффинные t-клеточные рецепторы человека - Google Patents

Сконструированные высокоаффинные t-клеточные рецепторы человека Download PDF

Info

Publication number
RU2729383C2
RU2729383C2 RU2016124163A RU2016124163A RU2729383C2 RU 2729383 C2 RU2729383 C2 RU 2729383C2 RU 2016124163 A RU2016124163 A RU 2016124163A RU 2016124163 A RU2016124163 A RU 2016124163A RU 2729383 C2 RU2729383 C2 RU 2729383C2
Authority
RU
Russia
Prior art keywords
tcr
cell receptor
cell
modified
cells
Prior art date
Application number
RU2016124163A
Other languages
English (en)
Russian (ru)
Other versions
RU2016124163A (ru
Inventor
Шина Н. СМИТ
Даниэль Т. ХАРРИС
Дэвид М. КРАНЦ
Original Assignee
Зэ Борд оф Трастиз оф зэ Юниверсити оф Иллинойс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зэ Борд оф Трастиз оф зэ Юниверсити оф Иллинойс filed Critical Зэ Борд оф Трастиз оф зэ Юниверсити оф Иллинойс
Publication of RU2016124163A publication Critical patent/RU2016124163A/ru
Application granted granted Critical
Publication of RU2729383C2 publication Critical patent/RU2729383C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2016124163A 2013-11-22 2014-11-21 Сконструированные высокоаффинные t-клеточные рецепторы человека RU2729383C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907887P 2013-11-22 2013-11-22
US61/907,887 2013-11-22
PCT/US2014/066892 WO2015077607A1 (en) 2013-11-22 2014-11-21 Engineered high-affinity human t cell receptors

Publications (2)

Publication Number Publication Date
RU2016124163A RU2016124163A (ru) 2017-12-27
RU2729383C2 true RU2729383C2 (ru) 2020-08-06

Family

ID=53180203

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2016124163A RU2729383C2 (ru) 2013-11-22 2014-11-21 Сконструированные высокоаффинные t-клеточные рецепторы человека
RU2016124179A RU2740648C2 (ru) 2013-11-22 2014-11-21 Сконструированные высокоаффинные t-клеточные рецепторы человека

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2016124179A RU2740648C2 (ru) 2013-11-22 2014-11-21 Сконструированные высокоаффинные t-клеточные рецепторы человека

Country Status (20)

Country Link
US (4) US10023625B2 (enExample)
EP (2) EP3071594A4 (enExample)
JP (4) JP6476182B2 (enExample)
KR (2) KR20160085345A (enExample)
CN (2) CN105873945B (enExample)
AU (4) AU2014352834B2 (enExample)
BR (1) BR112016011567A2 (enExample)
CA (2) CA2930847A1 (enExample)
DK (1) DK3071593T3 (enExample)
ES (1) ES2729406T3 (enExample)
IL (2) IL245468B (enExample)
MX (3) MX383471B (enExample)
PL (1) PL3071593T3 (enExample)
PT (1) PT3071593T (enExample)
RU (2) RU2729383C2 (enExample)
SA (1) SA516371174B1 (enExample)
SG (2) SG10201804335QA (enExample)
TR (1) TR201908404T4 (enExample)
WO (2) WO2015077615A1 (enExample)
ZA (2) ZA201603116B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
EP3520810A3 (en) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
LT2945647T (lt) 2013-01-15 2021-02-25 Memorial Sloan Kettering Cancer Center Imunogeniniai wt-1 peptidai ir jų panaudojimo būdai
JP6476182B2 (ja) 2013-11-22 2019-02-27 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 改変された高親和性ヒトｔ細胞受容体
AU2016325384B2 (en) * 2015-09-22 2021-07-22 Julius-Maximilians-Universitat Wurzburg A method for high level and stable gene transfer in lymphocytes
CA2998270A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017112944A1 (en) * 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
JP7054397B2 (ja) * 2016-06-27 2022-04-13 ジュノー セラピューティクス インコーポレイテッド Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
AU2017356322B2 (en) * 2016-11-14 2023-09-21 Fred Hutchinson Cancer Center High affinity merkel cell polyomavirus T antigen-specific TCRs and uses thereof
AU2018234830B2 (en) * 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
EA201992536A1 (ru) * 2017-04-24 2020-03-05 Оспедале Сан Раффаэле С.Р.Л. Tcr и пептиды
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
JP7598312B2 (ja) * 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
BR112021017703A8 (pt) 2019-03-11 2023-04-18 Hutchinson Fred Cancer Res Receptores de células t wt1 de alta avidez e usos dos mesmos
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
KR20220050176A (ko) * 2019-08-20 2022-04-22 프레드 헛친슨 켄서 리서치 센터 Wt-1에 특이적인 t-세포 면역요법
BR112022015982A2 (pt) * 2020-02-12 2022-10-11 Abbvie Inc Moléculas de ligação bispecíficas
AU2021262547A1 (en) 2020-04-28 2022-11-10 Achilles Therapeutics Uk Limited T cell therapy
CN112239495B (zh) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 稳定的tcr结构及应用
US20220323500A1 (en) 2021-04-09 2022-10-13 Achilles Therapeutics Uk Limited Cancer immunotherapy
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
KR20240023426A (ko) 2021-06-22 2024-02-21 아킬레스 테라퓨틱스 유케이 리미티드 항원-특이적 t 세포를 생산하는 방법
JP2024526836A (ja) * 2021-07-19 2024-07-19 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｆａｎｃｉ、ｒａｄ５１、およびｐｂｋ抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法
CN119220425A (zh) * 2023-07-28 2024-12-31 佳吾益(北京)科技有限公司 发现mhc新抗原肽表位的工程化细胞
WO2026102048A1 (en) * 2024-11-06 2026-05-15 The Regents Of The University Of California Engineered t cell receptor against insulin producing cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA008026B1 (ru) * 2003-01-30 2007-02-27 СУРВАК АпС Производные от сурвивина пептиды и их применение
US20080125369A1 (en) * 2001-08-31 2008-05-29 Avidex Limited Soluble t cell receptors
WO2010075417A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
US20120128704A1 (en) * 2009-02-09 2012-05-24 Max-Delbrueck-Centrum Fuer Molekulare Medizin Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3927193A (en) 1973-05-18 1975-12-16 Hoffmann La Roche Localization of tumors by radiolabelled antibodies
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4361544A (en) 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4468457A (en) 1981-06-01 1984-08-28 David M. Goldenberg Method for producing a CSAp tryptic peptide and anti-CSAp antibodies
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4640561A (en) 1985-11-15 1987-02-03 Ford Motor Company Flexible printed circuit connector
US5059413A (en) 1988-04-18 1991-10-22 Xoma Corporation Scintigraphic monitoring of immunotoxins using radionuclides and heterobifunctional chelators
CA2065299C (en) 1989-08-09 2001-07-24 Buck A. Rhodes Direct radiolabeling of antibodies and other proteins with technetium or rhenium
US5299253A (en) 1992-04-10 1994-03-29 Akzo N.V. Alignment system to overlay abdominal computer aided tomography and magnetic resonance anatomy with single photon emission tomography
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US6759243B2 (en) 1998-01-20 2004-07-06 Board Of Trustees Of The University Of Illinois High affinity TCR proteins and methods
NZ507886A (en) 1998-05-19 2003-05-30 Avidex Ltd Multivalent T cell receptor complexes
EP1124568B1 (en) 1998-10-21 2007-08-22 Altor BioScience Corporation Polyspecific binding molecules and uses thereof
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
GB0328363D0 (en) * 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
NZ550815A (en) 2004-05-19 2009-04-30 Immunocore Ltd Method of improving T cell receptors
WO2005113595A2 (en) 2004-05-19 2005-12-01 Avidex Ltd High affinity ny-eso t cell receptor
GB0524477D0 (en) * 2005-11-30 2006-01-11 Avidex Ltd Isolated T cell receptors which specifically bind to vygfvracl-hla-24
GB0511124D0 (en) 2005-06-01 2005-07-06 Avidex Ltd High affinity melan-a t cell receptors
AT503861B1 (de) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
WO2008039818A2 (en) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Modified t cell receptors and related materials and methods
US9281917B2 (en) 2007-01-03 2016-03-08 Nokia Technologies Oy Shared control channel structure
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
GB0911566D0 (en) 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
JP2013535199A (ja) 2010-07-28 2013-09-12 イムノコア リミテッド Ｔ細胞レセプター
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
WO2014191465A1 (en) * 2013-05-28 2014-12-04 Møller Niels Iversen Peptides derived from lawsonia intracellularis and their use in vaccination
PL228457B1 (pl) 2013-08-30 2018-03-30 Univ Jagiellonski Tomograf hybrydowy TOF-PET/CT
JP6476182B2 (ja) 2013-11-22 2019-02-27 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 改変された高親和性ヒトｔ細胞受容体
EP3177314B1 (en) 2014-08-04 2020-10-07 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
CN113105562B (zh) * 2018-09-26 2023-12-01 安源医药科技（上海）有限公司 突变型单链人凝血因子viii在制备融合蛋白中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080125369A1 (en) * 2001-08-31 2008-05-29 Avidex Limited Soluble t cell receptors
EA008026B1 (ru) * 2003-01-30 2007-02-27 СУРВАК АпС Производные от сурвивина пептиды и их применение
WO2010075417A1 (en) * 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
US20120128704A1 (en) * 2009-02-09 2012-05-24 Max-Delbrueck-Centrum Fuer Molekulare Medizin Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
LEISEGANG M. et al. "MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors." The Journal of clinical investigation, 2010, 120(11): 3869-3877. *
LEISEGANG M. et al. "MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors." The Journal of clinical investigation, 2010, 120(11): 3869-3877. SHEN HAN et al. "Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen." Cancer Immunology, Immunotherapy, 2013 (Published online: 29 August 2012), 62(2): 393-403. *
SCHENDEL D.J., FRANKENBERGER B. "Limitations for TCR gene therapy by MHC-restricted fratricide and TCR-mediated hematopoietic stem cell toxicity." Oncoimmunology, January 2013, 2(1): e22410. *
SHEN HAN et al. "Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen." Cancer Immunology, Immunotherapy, 2013 (Published online: 29 August 2012), 62(2): 393-403 *

Also Published As

Publication number Publication date
BR112016011583A2 (pt) 2017-09-26
SG10201804335QA (en) 2018-06-28
US20220396606A1 (en) 2022-12-15
US20160280756A1 (en) 2016-09-29
SG10201804330YA (en) 2018-07-30
JP2017501129A (ja) 2017-01-12
EP3071594A4 (en) 2017-05-03
US20160280755A1 (en) 2016-09-29
NZ719707A (en) 2020-09-25
EP3071593A4 (en) 2017-05-03
PT3071593T (pt) 2019-06-27
EP3071594A1 (en) 2016-09-28
JP6476182B2 (ja) 2019-02-27
AU2014352834A1 (en) 2016-05-26
JP6697386B2 (ja) 2020-05-20
DK3071593T3 (da) 2019-06-11
EP3071593B1 (en) 2019-03-13
US10023625B2 (en) 2018-07-17
WO2015077615A1 (en) 2015-05-28
CN105873945A (zh) 2016-08-17
JP2022023196A (ja) 2022-02-07
IL245467A0 (en) 2016-06-30
JP2017501130A (ja) 2017-01-12
AU2021202274A1 (en) 2021-05-06
RU2740648C2 (ru) 2021-01-19
CN105873945B (zh) 2020-07-17
MX2016006625A (es) 2016-12-02
CA2930847A1 (en) 2015-05-28
AU2019272003A1 (en) 2019-12-19
AU2014352826A1 (en) 2016-05-26
IL245468B (en) 2020-10-29
US20190055298A1 (en) 2019-02-21
CN105899530A (zh) 2016-08-24
JP6970724B2 (ja) 2021-11-24
PL3071593T3 (pl) 2019-11-29
US10344075B2 (en) 2019-07-09
BR112016011567A2 (pt) 2017-10-24
MX2021006932A (es) 2021-07-07
ZA201603169B (en) 2020-05-27
TR201908404T4 (tr) 2019-07-22
KR102415259B1 (ko) 2022-06-30
AU2014352826B2 (en) 2019-08-01
CA2930852C (en) 2024-01-23
KR20160087866A (ko) 2016-07-22
IL245468A0 (en) 2016-06-30
NZ719720A (en) 2020-09-25
MX371202B (es) 2020-01-22
MX2016006620A (es) 2017-05-11
AU2014352834B2 (en) 2019-08-29
ES2729406T3 (es) 2019-11-04
SA516371174B1 (ar) 2019-04-14
CN105899530B (zh) 2020-05-08
RU2016124163A (ru) 2017-12-27
IL245467B (en) 2020-04-30
WO2015077607A1 (en) 2015-05-28
CA2930852A1 (en) 2015-05-28
MX383471B (es) 2025-03-14
EP3071593A1 (en) 2016-09-28
RU2016124179A (ru) 2017-12-27
KR20160085345A (ko) 2016-07-15
AU2019272003B2 (en) 2021-05-06
ZA201603116B (en) 2018-12-19
JP2020007374A (ja) 2020-01-16

Similar Documents

Publication Publication Date Title
US20220396606A1 (en) Engineered high-affinity human t cell receptors
AU2018200222B2 (en) Engineering T-cell receptors
CA2880098C (en) Engineering t-cell receptors
HK1228412B (en) Engineered high-affinity human t cell receptors
HK1228412A1 (en) Engineered high-affinity human t cell receptors
NZ719707B2 (en) Engineered human t cell receptors with high affinity for binding survivin
NZ719720B2 (en) Engineered human t cell receptors with high affinity for wt1